Balipodect

DB14774InvestigationalSmall molecule

Balipodect is under investigation in clinical trial NCT01892189 (Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults).

Mechanism: Pharmacologically active on cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A
Curator reviewed
Formula / weight: C₂₃H₁₇FN₆O₂ · 428.427 g/mol (avg)
Code names: TAK-063

Resolves to

Compound

UNII6650W303H0CAS1238697-26-1ChEMBLCHEMBL3989972

Structure

InChIKeyKVHRYLNQDWXAGI-UHFFFAOYSA-NSMILESCOC1=CN(N=C(C2=CC=NN2C2=CC=CC=C2)C1=O)C1=CC=C(C=C1F)N1C=CC=N1

Targets

Q9Y233PDE10A

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Balipodect, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account